{"id":"tqb2440-injection-trastuzumab-docetaxel","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Neutropenia"},{"rate":"5-20%","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TQB2440 injection's mechanism of action involves binding to PD-1, preventing its interaction with PD-L1 and thereby unleashing the immune system to attack cancer cells. Trastuzumab, on the other hand, binds to the HER2/neu receptor on cancer cells, causing cell death. Docetaxel works by inhibiting the microtubule dynamics, which is essential for cell division, ultimately leading to cell death.","oneSentence":"TQB2440 injection is a targeted therapy that works by inhibiting the PD-1/PD-L1 pathway, while Trastuzumab is a monoclonal antibody that targets the HER2/neu receptor, and Docetaxel is a chemotherapy medication that works by inhibiting cell division.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:37.260Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced or metastatic HER2-positive breast cancer"},{"name":"Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma"}]},"trialDetails":[{"nctId":"NCT03199885","phase":"PHASE3","title":"Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-05","conditions":"Metastatic Breast Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma, Recurrent Breast Adenocarcinoma","enrollment":190},{"nctId":"NCT02003209","phase":"PHASE3","title":"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-02-18","conditions":"HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7","enrollment":315},{"nctId":"NCT05985187","phase":"PHASE3","title":"Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-10-20","conditions":"HER2-positive Breast Cancer","enrollment":412}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TQB2440 injection + Trastuzumab + Docetaxel","genericName":"TQB2440 injection + Trastuzumab + Docetaxel","companyName":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","companyId":"chia-tai-tianqing-pharmaceutical-group-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TQB2440 injection is a targeted therapy that works by inhibiting the PD-1/PD-L1 pathway, while Trastuzumab is a monoclonal antibody that targets the HER2/neu receptor, and Docetaxel is a chemotherapy medication that works by inhibiting cell division. Used for Locally advanced or metastatic HER2-positive breast cancer, Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}